

Evropská unie Evropský sociální fond Operační program Zaměstnanost







Development of Czech National Stroke Guidelines

Radim Licenik, J. Bednarik, A. Tomek, M. Bar, J. Neumann, D. Sanak, T. Necas, P. Burilova, J. Klugarova, A. Pokorna, M. Klugar

European JBI symposium of Evidence-Based Healthcare in Clinical Practice Guidelines, Decision making process and Evidence synthesis in the Czech Republic, Brno, 12th – 14th December 2018





Disclosure

- I have no conflicts of interest





MUNI MED

Development of Czech National Stroke Guidelines

WHY WE DID WHAT WE DID?







YLLs = years of life lost

Leading causes 1990	Leading causes 2005	% change	Median all-age % change	Age- standard- ised % change		Leading causes 2015	% change	Median all-age % change	Age- standard- ised % change
1 Lower respiratory infections	1 Ischaemic heart disease	25-8	2.3	-12-6		1 Ischaemic heart disease	-10-2	-2.5	-14-8
2 Neonatal preterm birth complications	2 Lower respiratory infections	-37-3	-49-0	-37.5		2 Cerebrovascular disease	-0.9	-12.4	-23-0
3 Diarrhoeal diseases	3 Cerebrovascular disease	21.2	-1-4	-13-3		3 Lower respiratory infections	-23.9	-32.7	-31-1
4 Ischaemic heart disease	4 HIV/AIDS	597-5	467.3	458.7		4 Neonatal preterm birth complications	-25.9	-34.5	-29-8
5 Cerebrovascular disease	5 Neonatal preterm birth complications	-39-4	-50.7	-37.4		5 Diarrhoeal diseases	-29.2	-37-4	-35-8
6 Neonatal encephalopathy	6 Diarrhoeal diseases	-38-5	-50-0	-40-4	· ·	6 Neonatal encephalopathy	-16-1	-25-8	-20-5
7 Malaria	7 Malaria	21-1	-1-5	19-1	./	7 HIV/AIDS	-33-9	-41.5	-41-4
8 Measles	8 Neonatal encephalopathy	-3.5	-21.6	-0.3	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	8 Road injuries	-8-1	-18.7	-18-5
9 Congenital anomalies	9 Road injuries	11.0	-9.7	-7.8		9 Malaria	-40-1	-47.0	-44.7
10 Road injuries	10 COPD	-4-6	-22.4	-30-1		10 COPD	-3.0	-14-2	-25-0

Communicable, maternal, neonatal, nutritional

Non-communicable disease



1990

Injuries

MUNI MED

YLLs = years of life lost

Leading causes 1990	Leading causes 2005	% change	Median all-age % change	Age- standard- ised % change		Leading causes 2015	% change	Median all-age % change	Age- standard- ised % change
1 Lower respiratory infections	1 Ischaemic heart disease	25-8	2.3	-12.6		1 Ischaemic heart disease	-10-2	-2.5	-14-8
2 Neonatal preterm birth complications	2 Lower respiratory infections	-37-3	-49-0	-37.5		2 Cerebrovascular disease	-0.9	-12.4	-23-0
3 Diarrhoeal diseases	3 Cerebrovascular disease	21.2	-1-4	-13-3		3 Lower respiratory infections	-23.9	-32.7	-31-1
4 Ischaemic heart disease	4 HIV/AIDS	597-5	467.3	458.7		4 Neonatal preterm birth complications	-25.9	-34.5	-29-8
5 Cerebrovascular disease	5 Neonatal preterm birth complications	-39-4	-50.7	-37.4		5 Diarrhoeal diseases	-29-2	-37-4	-35-8
6 Neonatal encephalopathy	6 Diarrhoeal diseases	-38.5	-50-0	-40.4	· ·	6 Neonatal encephalopathy	-16-1	-25-8	-20-5
7 Malaria	7 Malaria	21.1	-1-5	19.1	./	7 HIV/AIDS	-33-9	-41.5	-41-4
8 Measles	8 Neonatal encephalopathy	-3.5	-21.6	-0.3	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	8 Road injuries	-8-1	-18.7	-18-5
9 Congenital anomalies	9 Road injuries	11.0	-9.7	-7.8		9 Malaria	-40-1	-47.0	-44.7
10 Road injuries	10 COPD	-4-6	-22.4	-30-1		10 COPD	-3.0	-14-2	-25-0

Non-communicable disease

Communicable, maternal, neonatal, nutritional

Masaryk University GRADE Centre

2017

Injuries

MUNI MED

Leading ten causes of YLLs


	1	2	3	4	5	6	7
Clabel	IHD	Stroke	LRI	NN preterm	Diarrhoea	NN encephalitis	HIV
Global	(0.98)	(0.98)	(0-67)	(0.72)	(0.74)	(1.18)	(0.63)
High SDI	IHD	Stroke	Lung C	Self-harm	Alzheimer's	LRI	Colorect C
	(1.58)	(1.09)	(1.08)	(0.94)	(0.98)	(0.81)	(0.86)
High-middle SDI	IHD	Stroke	Road injuries	Lung C	LRI	HIV	COPD
nigh-fillidale 501	(0.88)	(0.92)	(0.9)	(0.93)	(0.81)	(0.51)	(1.12)
Middle SDI	IHD	Stroke	Road injuries	COPD	LRI	NN preterm	Congenital
	(0-8)	(1.15)	(0.73)	(1.37)	(0-6)	(0-7)	(0.74)
Low-middle SDI	LRI	Nivencephailtis	Diarrhoea	NN preterm	IHD	HIV	Malaria
	(0.77)	(1.5)	(1.02)	(0.79)	(1.02)	(0.71)	(15.93)
Low SDI	LRI	Malaria	Diarrhoea	HIV	NN preterm	NN encephalitis	Congenital
	(0.53)	(2.96)	(0-45)	(1.62)	(0.51)	(0.68)	(0.93)
High income	IHD	Lung C	Stroke	Alzheimer's	Self-harm	COPD	LRI
	(1.08)	(1.05)	(0.7)	(1.04)	(0.81)	(1.46)	(0.75)





MUNI

MED



MED






















Big black or big white hole









TYPES OF STOKES





MANAGEMENT OF ISCHAEMIC STROKE OR TIA




















TYPES AND CAUSES OF STOKES






Atrial fibrillation \rightarrow cause of cardioembolic ischaemic stroke



Centre



1. Gattellari M et al. Cerebrovasc Dis. 2011;32:370-382.


Marini C et al. Stroke. 2005;36:1115-1119.





MUNI

MED



1. Direct oral anticoagulants











2. Vitamin k antagonists



WHY WE DID WHAT WE DID?



MED







HIGH PREVALENCE SEVERE CONSEQUENCES

STROKE



ISCHAEMIC STROKE

 CARDIOEMBOLIC ATRIAL FIBRILLATION



PRIMARY & SECONDARY PREVENTION

ANTICOAGULANTS

MUNI MED



Evropská unie Evropský sociální fond Operační program Zaměstnanost







CZECH NATIONAL GUIDELINE DEVELOPMENT PROGRAMME



Clinical practice guidelines development

YESTERDAYTODAYTOMORROW... from 1990's... to the 21st century





More systematic approach was needed.



Six topics for pilot guidelines development

CARDIOVASCULAR	NEUROLOGY	DIABETES
ACS	STROKE	MELLITUS
ONCOLOGY	HAEMATOLOGY	ONE DAY
COLORECTAL CA	CLL	SURGERY



Evropská unie Evropský sociální fond Operační program Zaměstnanost







CZECH NATIONAL STROKE GUIDELINE DEVELOPMENT



Process of guideline development

- 1. Planning and preparation
- 2. Development
- 3. Dissemination publication

4. Evaluation and update

Planning and preparation phase – guideline development group

Guarantor

Prof J Bednarik, *President of the Czech Neurological Society*

Authors	Dr A Tomek
Stroke	Prof M Bar
neurologists	Prof D Sanak
	Dr J Neumann
Methodologists	Dr R Licenik

Dr T Necas

Dr P Burilova



Planning and preparation phase – multidisciplinary panel


Cardiologist Prof M Taborsky

President of the Czech Society of Cardiology

Clinical Dr J Strojil pharmacologist

-	
GP, general internal and emergency medicine	Dr D Stoszek
Non-health care professional; researcher, immunologist	Prof V Horejsi

Development phase – health question determination 1



Development phase – health question determination 2

Ρ	Adult patients with cardiembolic stroke and non-valvular
	atrial fibrillation
I	Direct oral anticoagulants
С	Warfarin
Ο	Ischaemic stroke, systemic embolisation, major
	haemorrhage

Development phase – health question determination 3

Ρ	Adult patients with cardiembolic stroke and non-valvular
	atrial fibrillation
	Warfarin
С	Antiplatelets
	le che omie stroke svotemie ombeligetien intropresiel and
0	Ischaemic stroke, systemic embolisation, intracranial and
	major extracranial haemorrhage

Development phase – search guidelines

✓PubMed ✓National Guidelines Clearinghouse ✓G-I-N **√NICE √SIGN √WSO, ESO, ASF**

Development phase – screening & quality assessment


- 1. Are there any relevant guidelines already developed?
- 2. Are they up-to date and developed using **GRADE**



Development phase – screening & quality assessment


Are there any relevant guidelines already developed?





Development phase – screening & quality assessment

What is the methodological quality of the guideline?



HODNOCENÍ DOPORUČENÝCH POSTUPŮ PRO VÝZKUM A EVALUACI II




AGREE II NÁSTROJ

Překlad do českého jazyka

The AGREE Next Steps Consortium

Centrum pro klinické doporučené postupy Ústav sociálního lékařství a zdravotní politiky Lékařská fakulta Univerzity Palackého v Olomouci Říjen 2013



Development phase – decision to adopt or adapt

Is the guideline suitable for adoption or adaptation?



Development phase – decision to adopt or adapt ADOPTION vs. ADAPTATION

Similar population & health conditions
Same interventions & comparison

•More specific recommendations needed

based on authors' consensus

Different implementation strategies needed


Development phase – decision to adopt or adapt

Is the guideline suitable for adoption or adaptation?



Development phase – decision to adopt or adapt

ADAPTATION











Ischemická cévní mozková příhoda nebo tranzitorní ischemická ataka kardioembolické etiologie a jejich sekundární prevence.

Adaptovaný klinický doporučený postup

Doporučený postup pro péči o pacienty s cévní mozkovou příhodou 2017 Australian Stroke Foundation Kapitola 4 Sekundární prevence; Antikoagulační léčba

Autoři:

prof. MUDr. Josef Bednařík, CSc., FCMA (garant) prim. MUDr. Aleš Tomek, Ph.D., FESO, doc. MUDr. Michal Bar, Ph.D., FESO, prim. MUDr. Jiří Neumann, doc. MUDr. Daniel Šaňák, Ph.D., FESO (autoři) MUDr. Mgr. Radim Líčeník, Ph.D. (hlavní metodik) MUDr. Tomáš Nečas, PhDr. Petra Búřilová (metodici) 1.0 30. 11. 2018

Clinical Guidelines for Stroke Management 2017

Chapter 4 of 8: Secondary prevention

Verze: Datum:

• For ischaemic stroke or TIA patients with atrial fibrillation (both paroxysmal and permanent), oral anticoagulation is recommended for long-term secondary prevention. (Saxena et al 2004 [103]; Saxena 2004 [104]; Ruff et al 2014 [88]) Strong for recommendation $\oplus \oplus \oplus \oplus$ • Direct oral anticoagulants (DOACs) should be initiated in preference to warfarin for patients with non-valvular atrial fibrillation and adequate renal function. (Ruff et al 2014 [88]) Strong for recommendation $\oplus \oplus \oplus \oplus$ • For patients with valvular atrial fibrillation or inadequate renal function, warfarin (target INR 2.5, range 2.0-3.0) should be used. Patients with mechanical heart valves or other indications for anticoagulation should be prescribed warfarin. (Tawfik et al 2016) [117])

Strong for recommendation

 $\oplus \oplus \oplus \oplus$

MUNI MED


WHAT ARE WE GOING TO DO NEXT?








MUNI Med





THANK YOU ③

radim.licenik@gmail.com radim.licenik@nhs.net








MUNI MED

Complications During Hospital Stay for Acute Ischemic Stroke









MUNI MED